- Sputnik International, 1920
World
Get the latest news from around the world, live coverage, off-beat stories, features and analysis.

Risk to Contract COVID-19 Remains for 3 Weeks After 2nd Sputnik V Shot, Developer Says

© Sputnik / Grigory Sysoev / Go to the mediabankA healthcare worker prepares a dose of Russia's coronavirus vaccine Gam-COVID-Vac, trade-named Sputnik V, at a coronavirus vaccination center at a shopping mall, in Moscow, Russia.
A healthcare worker prepares a dose of Russia's coronavirus vaccine Gam-COVID-Vac, trade-named Sputnik V, at a coronavirus vaccination center at a shopping mall, in Moscow, Russia. - Sputnik International, 1920, 05.04.2021
Subscribe
MOSCOW (Sputnik) - The possibility of getting infected with the coronavirus remains 3 weeks after receiving second shot of Sputnik V vaccine, however, the disease manifests itself only with mild symptoms in such cases, Alexander Gintsburg, the head of the Russian Gamaleya Research Institute, which developed vaccine, said.

"In what cases, after vaccination, a person can get sick? If three weeks after the first vaccination or three weeks after the second vaccination [with Sputnik V] have not yet passed. As a rule, if after the second vaccination a person falls ill within three weeks, when the immune system has not yet fully formed, then, as practice shows, they get sick in a mild form," Gintsburg said.

The researcher specified that if a person contracts the coronavirus within three to five days after the first inoculation, the symptoms might be more severe, so it is vital to comply with protective measures until the immune system is fully developed.

The second shot of the Russian vaccine gives a hundred percent protection against the severe form of the virus after three post-vaccination weeks expire, Gintsburg added.

Sputnik V was registered by the Russian Health Ministry in August 2020, becoming the world's first vaccine against the coronavirus. The drug's effectiveness after the third phase of the clinical trials was proved to be nearly 92 percent, according to trial results released The Lancet medical journal. The vaccine has so far been approved for use in 59 countries.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала